title: A pilot study examining short-term changes in bone mineral density among class 3 obese users of depot-medroxyprogesterone acetate.
abstract: OBJECTIVE
  To examine changes in lumbar spine-bone mineral density (LS-BMD) among normal weight (body mass index [BMI] = 18.5-24.9 kg/m(2)), Class 1-2 obese (BMI = 30-39.9 kg/m(2)), and Class 3 obese (BMI ≥ 40 kg/m(2)) women utilising depot-medroxyprogesterone acetate (DMPA).
  
  
  METHODS
  Five normal-weight, five Class 1-2 obese, and five Class 3 obese women received subcutaneous injections of DMPA-SC at baseline and 12 weeks later. Dual Energy X-ray Absorptiometry (DEXA) scans were performed at baseline and 18 weeks after the first injection for determination of LS-BMD and analysis of fat content. Bimonthly oestradiol (E2) levels were measured by immunoassay methods for 26 weeks.
  
  
  RESULTS
  There were no significant demographic or LS-BMD differences among the three BMI groups. Significant differences at baseline were as expected among the three groups with respect to BMI and associated parameters (mean % total body fat, absolute fat, and weight). When used as their own controls, significant changes in LS-BMD, % body fat and absolute fat determined by DEXA occurred among all three BMI strata. Class 1-2 obese and Class 3 obese women were more likely to experience E2 fluctuations, but short-term changes in LS-BMD were similar.
  
  
  CONCLUSIONS
  DMPA-SC administration affects L-spine bone health similarly regardless of BMI status.
authors.affiliation: Keck School of Medicine, University of Southern California, Los Angeles, California, USA. psegall@usc.edu
authors.forename: Penina
authors.initials: P
authors.lastname: Segall-Gutierrez
authors.forename: Reshem
authors.initials: R
authors.lastname: Agarwal
authors.forename: Marshall
authors.initials: M
authors.lastname: Ge
authors.forename: Claudia
authors.initials: C
authors.lastname: Lopez
authors.forename: Gerson
authors.initials: G
authors.lastname: Hernandez
authors.forename: Frank Z
authors.initials: FZ
authors.lastname: Stanczyk
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D001823:Body Composition / Q000187:drug effects; D015992:Body Mass Index; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D016022:Case-Control Studies; D003271:Contraceptive Agents, Female / Q000009:adverse effects* / Q000494:pharmacology; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000097:blood / Q000502:physiology; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects* / Q000494:pharmacology; D009767:Obesity, Morbid / Q000097:blood / Q000378:metabolism*; D050177:Overweight / Q000097:blood / Q000378:metabolism*; D010865:Pilot Projects; D045167:Progesterone Congeners / Q000494:pharmacology; D013997:Time Factors; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D004967:Estrogens; D045167:Progesterone Congeners; D004958:Estradiol; D017258:Medroxyprogesterone Acetate